Applied Therapeutics Inc
NASDAQ:APLT

Watchlist Manager
Applied Therapeutics Inc Logo
Applied Therapeutics Inc
NASDAQ:APLT
Watchlist
Price: 9.9 USD -3.32% Market Closed
Market Cap: 1.1B USD
Have any thoughts about
Applied Therapeutics Inc?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-8.3
Current
-1.1
Median
4.3
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-8.3
=
Enterprise Value
1B USD
/
EBITDA
-121.6m USD
All Countries
Close
Market Cap EV/EBITDA
US
Applied Therapeutics Inc
NASDAQ:APLT
1.1B USD -8.3
FR
Pharnext SCA
OTC:PNEXF
6T USD -215 743.3
US
Abbvie Inc
NYSE:ABBV
302.3B USD 14.9
US
Amgen Inc
NASDAQ:AMGN
160.6B USD 17.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.3B USD 26.7
US
Gilead Sciences Inc
NASDAQ:GILD
118.3B USD 10.4
US
Epizyme Inc
F:EPE
94.1B EUR -523.7
AU
CSL Ltd
ASX:CSL
138.5B AUD 21.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
90.4B USD 17.9
US
Seagen Inc
F:SGT
39.3B EUR -59.8
NL
argenx SE
XBRU:ARGX
33.4B EUR -102.8
EBITDA Growth
US
Applied Therapeutics Inc
NASDAQ:APLT
Average EV/EBITDA: 18.1
Negative Multiple: -8.3
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -215 743.3 N/A
US
Abbvie Inc
NYSE:ABBV
14.9
28%
US
Amgen Inc
NASDAQ:AMGN
17.7
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.7
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.4
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -523.7 N/A
AU
CSL Ltd
ASX:CSL
21.1
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.8 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -102.8 N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-12.6
2-Years Forward
EV/EBITDA
-17.9
3-Years Forward
EV/EBITDA
30.1

See Also

Discover More